 TEMPLE CITY, Calif.--BUSINESS WIRE--Fulgent Genetics, Inc. NASDAQ: FLGT Fulgent Genetics or the Company, a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its first quarter 2022 financial results after the market closes on Tuesday, May 3, 2022. The companys Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, Chief Commer 